250,000 babies immunized, and how many hospitalizations avoided?
Government, doctors, parents and observers are asking this same question, while the annual epidemic of bronchiolitis among toddlers has ended.
With a big novelty this year: the arrival of Beyfortus, developed by the Sanofi and AstraZeneca laboratories.
Many parents have rushed - sometimes in vain - for this preventive treatment supposed to protect against respiratory syncytial virus (RSV), the main cause of this respiratory disease.
“All the signals we have point in the same direction: that of the strong effectiveness of Beyfortus, which seems to keep its promise,” rejoices Christèle Gras Le Guen, former president of the French Pediatric Society.
Subscribe
Already subscribed?
To log in